



S2Medical wins procurement in Femklövern worth up to 6 MSEK

S2Medical AB (publ) ("The Company") has won a procurement for wound healing products in the five Swedish regions collectively referred to as Femklövern. The products that have been procured is Ynolens perfume free odor remover which is produced by a third party supplier to The Company. The procurement will run over a maximum of 4 years and is estimated to be worth up to 6 MSEK. The value of the procurement is based on previously consumed volumes.

The Company has, as previously announced, signed a distribution agreement with Ynolens AS for their perfume free odor remover in Sweden, which among other things is used to reduce the patients' sufferings associated with wound treatments.

The stigma for wound related problems is strongly associated with foul odors from the wounds which has a significant negative effect on the patients' quality of life. Ynolens AS has developed a perfume free odor remover which helps healthcare personnel as well as patients to have an environment which is free from foul odors. The products have successfully been used on S2Clinic since its inauguration and is an integral part of S2Medicals wound healing concept.

"It is a fantastic feeling that this product as well is winning grounds in Sweden. Femklövern constitutes a large group of hospitals and health centers and the value of the procurement is therefor relatively high", says The Company's CEO Petter Sivlér

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-06-2022 14:13 CET.

Contact Details

Petter Sivlér – CEO, S2Medical AB (publ)

Telephone: +46 (0)8-70 000 50

E-mail: petter.sivler@s2m.se

Certified Adviser

Vator Securities AB

Telephone +46 (0)8-580 065 99

Website: www.vatorsec.se

E-mail: ca@vatorsec.se

About S2Medical

S2Medical AB (publ) is a medical technology company that develops and sells innovative wound healing products for the entire wound healing process, with a focus on burns and chronic wounds. The company has developed eiratex®, a new cellulose-based material for healing severe burns and chronic wounds. The material heals wounds effectively and thereby reduces both suffering for patients and costs for health

care.

Share's ticker: S2M

Share's ISIN-code: SE0011725084